6533b82afe1ef96bd128c398

RESEARCH PRODUCT

Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors

Andre WeilemannMarie Luise GebhardtMichael GrauCarsten Müller-tidowMelinda CzehGeorg LenzVerena GröningMiguel A. Andrade-navarroPia RiemkeJosephine FischerSaeed GhaniFrank RosenbauerMartin DugasMatthias ZepperDido LenzeNancy MahTorsten HaferlachStephanie LettermannRuud DelwelKonstantin AgelopoulosMarco PrinzCarolin Walter

subject

0301 basic medicineMyeloidBone Marrow CellsBiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceshemic and lymphatic diseasesmedicineCell LineageProgenitor cellMolecular BiologyGeneral Immunology and MicrobiologyGeneral NeuroscienceTransdifferentiationMyeloid leukemiaCell DifferentiationArticlesmedicine.diseaseHematopoietic Stem CellsHaematopoiesisLeukemia030104 developmental biologymedicine.anatomical_structureImmunologyCancer researchLymphoid Progenitor CellsStem cell

description

Unfavorable patient survival coincides with lineage plasticity observed in human acute leukemias. These cases are assumed to arise from hematopoietic stem cells, which have stable multipotent differentiation potential. However, here we report that plasticity in leukemia can result from instable lineage identity states inherited from differentiating progenitor cells. Using mice with enhanced c-Myc expression, we show, at the single-cell level, that T-lymphoid progenitors retain broad malignant lineage potential with a high capacity to differentiate into myeloid leukemia. These T-cell-derived myeloid blasts retain expression of a defined set of T-cell transcription factors, creating a lymphoid epigenetic memory that confers growth and propagates myeloid/T-lymphoid plasticity. Based on these characteristics, we identified a correlating human leukemia cohort and revealed targeting of Jak2/Stat3 signaling as a therapeutic possibility. Collectively, our study suggests the thymus as a source for myeloid leukemia and proposes leukemic plasticity as a driving mechanism. Moreover, our results reveal a pathway-directed therapy option against thymus-derived myeloid leukemogenesis and propose a model in which dynamic progenitor differentiation states shape unique neoplastic identities and therapy responses.

10.15252/embj.201693927https://pure.eur.nl/en/publications/f8d14d8d-6cb0-44d5-9a86-8328c608f006